SMAD3 (phospho-Ser425) Antibody
- Known as:
- SMAD3 (phosphorilated-Ser425) Antibody
- Catalog number:
- abx000322
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Abbexa
- Gene target:
- SMAD3 (phospho-Ser425) Antibody
Related genes to: SMAD3 (phospho-Ser425) Antibody
- Gene:
- SMAD3 NIH gene
- Name:
- SMAD family member 3
- Previous symbol:
- MADH3
- Synonyms:
- JV15-2, HsT17436
- Chromosome:
- 15q22.33
- Locus Type:
- gene with protein product
- Date approved:
- 1996-11-15
- Date modifiied:
- 2016-10-05
Related products to: SMAD3 (phospho-Ser425) Antibody
Related articles to: SMAD3 (phospho-Ser425) Antibody
- Transforming growth factor-β (TGF-β) contributes to fibrosis, immunosuppression, and tumor progression, but systemic TGF-β inhibition is limited by toxicity and lack of selectivity. This exploratory proof-of-concept study evaluated novel peptides designed to target the TGF-β receptor I/II complex and examined their effects on canonical and noncanonical TGF-β signaling in vitro. Peptides 2_5 and 2_6, selected by in silico docking of receptor-ligand interface-derived sequences, were tested in human embryonic kidney 293T (HEK293T) cells at 20 and 50 μM, with the TGF-β receptor I inhibitor SD-208 as a reference. Total and phosphorylated SMAD2, SMAD3, extracellular signal-regulated kinase 1/2 (ERK1/2), and c-Jun N-terminal kinase (JNK) were assessed by Western blotting and densitometry. Peptide 2_5 showed the strongest activity, reducing total ERK1/2 by 65% at 50 μM and phosphorylated ERK1/2 by 90.4% and 83.4% at 20 and 50 μM, respectively; SD-208 reduced total and phosphorylated ERK1/2 by 64.3% and 54.5%, respectively. Peptide 2_5 also reduced total SMAD2 by 81% at 50 μM, whereas its effect on SMAD2 phosphorylation was inconsistent. Peptide 2_6 showed minimal effects, JNK was largely unaffected, and SMAD3 results were inconclusive because of weak signals. These preliminary findings suggest that peptide 2_5 may differentially modulate TGF-β signaling, with a stronger effect on ERK1/2 than on SMAD2; however, receptor targeting and pathway selectivity require confirmation in fully replicated quantitative studies. - Source: PubMed
Publication date: 2026/08/20
Plichta JacekKarbownik Michał SewerynKuna PiotrPanek Michał - Berberine (BBR), the core alkaloid of the traditional Chinese medicine (Huanglian), exhibits a notable pharmacological paradox: it possesses an oral bioavailability of less than 1% yet exerts broad therapeutic effects across the full spectrum of liver diseases, from metabolic dysfunction-associated steatotic liver disease (MASLD) through fibrosis to hepatic malignancies. This review constructs an integrated mechanistic framework to interpret BBR's holistic pharmacological characteristics, which distinguish it from conventional single-target drugs. In MASLD, BBR engages a convergent AMPK-SIRT-Nrf2 network to ameliorate insulin resistance, lipid dysregulation, oxidative stress, and hepatic inflammation. Combined with the complementary actions of its bioactive metabolites, it achieves parent-metabolite coordinated efficacy that embodies the holistic principle of traditional Chinese medicine. In liver fibrosis, BBR may block hepatic stellate cell activation via the TGF-β1/Smad3 pathway and eliminate activated HSCs through multiple programmed cell death pathways, particularly ferroptosis, which may overcome apoptosis resistance. In hepatic malignancies, BBR suppresses tumor progression, metastasis, and chemoresistance via apoptotic, ferroptotic, and immunomodulatory mechanisms. Current clinical evidence validates its metabolic benefits in MASLD, whereas clinical data regarding fibrosis and hepatic malignancies remain insufficient. Improving its poor bioavailability through structural modification and nanocarrier delivery is critical for clinical translation. This review provides a modern pharmacological rationale for the clinical application of -based formulas against progressive liver diseases. - Source: PubMed
Publication date: 2026/08/19
He HongxiaWu ShuyunYi Jiazhi - This study aimed to explore the ameliorative effects of enoxolone on renal fibrosis in diabetic kidney disease (DKD) and elucidate its underlying molecular mechanisms, thereby proposing a novel candidate drug and providing a theoretical foundation for clinical anti-fibrotic therapy in DKD. - Source: PubMed
Publication date: 2026/07/11
Lv BeiduoGuo ZhaochenChen ZigeLiu ZhihongBao Hao - Epidural fibrosis is a major cause of failed back surgery syndrome following laminectomy. While previous studies have focused primarily on the early phases of scar formation, fibrotic remodelling remains poorly understood. This study aimed to investigate the interaction between collagen accumulation and fibroblasts during the remodelling phase of epidural fibrosis. - Source: PubMed
Publication date: 2026/08/17
Huang YueSong ZeyuanMei XiaojieZhao YoupengZhu TaoShi MohanSun JinpengZhang MingshunWu TaoLiu Jun - The relatively low edible muscle yield and inconsistent flesh texture of red swamp crayfish limit its commercial value and highlight the need for effective nutritional interventions. Although L-carnosine has shown beneficial effects on muscle growth and quality in vertebrates, its nutritional functions and underlying mechanisms in crustaceans remain unclear. This study aimed to evaluate the effects of dietary L-carnosine on growth performance and muscle quality in red swamp crayfish (). A total of 324 red swamp crayfish, with an initial body weight of 6.19 ± 0.03 g, were randomly divided into 6 groups of three replicates and 54 crayfish per group (18 crayfish per replicate). Six experimental diets containing graded levels of L-carnosine (3.35, 59.28, 106.84, 222.20, 452.93, and 821.16 mg/kg) were fed for 8 weeks. Regression analysis revealed dose-dependent responses in multiple parameters. Weight gain rate, specific growth rate, protein efficiency ratio, protein deposition rate, muscle percentage, whole-body and muscle crude protein content, muscle textural properties (hardness and chewiness), hydroxyproline levels (alkaline-insoluble and total), myofiber density, small myofiber proportion (<50 μm), and total amino acid content exhibited quadratic trends ( < 0.05), with peak values observed in the 452.93 mg/kg group. Conversely, feed conversion ratio and large myofiber proportion (>70 μm) showed significant quadratic decreases ( < 0.05), reaching their lowest values at 452.93 mg/kg. Transcriptional analysis demonstrated that, compared with the 3.35 mg/kg L-carnosine group, the 452.93 mg/kg L-carnosine group significantly regulated genes involved in several key pathways: mTORC1 signaling (, , , , , and ), eIF2B-eIF2 signaling (), ubiquitin-proteasome system (, , , and ), autophagy-lysosomal system (, , , and ), TGFβ/Smads pathway (, , , , and ), and myogenic regulators (, , and ) ( < 0.05). These molecular modulations were consistent with observed phenotypic improvements. Overall, the findings demonstrated that a dietary L-carnosine level of 458.06 to 500.00 mg/kg, as determined by quadratic regression analysis, significantly enhances growth performance, feed utilization, muscle hardness and chewiness, and nutritive value in red swamp crayfish. - Source: PubMed
Publication date: 2026/08/05
Li XinyuanLiu YangyangXie ShouqiZhang JianminGao WeihuaJiang MingDong LixuePeng DiCheng KeHuang FengTian Juan